Laura Iulia Barcutean , Andreea Romaniuc*, Smaranda Maier , Zoltan Bajko , Anca Motataianu , Adina Hutanu , Iunius Simu, Sebastian Andone and Rodica Balasa Pages 780 - 792 ( 13 )
Introduction: We evaluated the peripheral immune panel of multiple sclerosis (MS) patients treated for more than 10 years with interferon-beta1b (IFNβ-1b) and aimed to identify possible biomarkers of treatment response.
Material and Methods: Serum samples from 70 MS patients treated with IFNβ-1b more than a decade were analysed for 15 cytokines, that were correlated with the disability score, annual relapse ratio (ARR): the total number of relapses-ARR_0, relapse on treatment-ARR_1 and demographic data. Two groups were defined based on the levels of disability, calculated using the Expanded Disability Status Scale (EDSS): G1 – recurrent-remissive and G2 – secondary-progressive. Furthermore, we split the patients based on gender (G1_f, G1_m, G2_f, G2_m).
Results: The ARR was reduced after treatment was instituted. We found positive correlations between IL_25 and EDSS in G1_f and G2_f, tumor necrosis factor α (TNFα) and ARR_1 and ARR_0 in G1, and IL_17F with ARR_1. Negative correlations were for IL_25 and ARR_0 and ARR_1. SCD40L intensely positively correlated with IL_31 in G1 and G2.
Conclusion: After more than a decade of treatment, IFNβ-1b offers good results by reducing relapses and slowing disability progression. Several biomarkers can be used to assess the patient’s response. High levels of IL_17 and TNFα will indicate a more active form of the disease. IL-25 may exert a positive influence in male MS patients and should be considered for future studies, together with the co-modulation between sCD40L and IL_31. Our method allowed us to screen the peripheral immune panel and can be used for assessing the peripheral levels of the above-mentioned cytokines.
Multiple sclerosis, inflammation, cytokines, interferon β-1b, relapses, evolution, disability
University of Medicine and Pharmacy, Targu Mures, First Department of Neurology, Emergency Clinical County Hospital, Targu Mures, University of Medicine and Pharmacy, Targu Mures, University of Medicine and Pharmacy, Targu Mures, University of Medicine and Pharmacy, Targu Mures, Center of Advanced Medical and Pharmaceutical Research, University of Medicine and Pharmacy Targu Mures, University of Medicine and Pharmacy, Targu Mures, First Department of Neurology, Emergency Clinical County Hospital, Targu Mures, University of Medicine and Pharmacy, Targu Mures